



ASX / Media Release  
5 December 2023

## Effective Date of Capital Return

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure today announces the Effective Date of the \$14.0 million capital return as announced on 1 November 2023 and approved by shareholders at a General Meeting of shareholders on 5 December 2023 will be 6 December 2023.

An indicative timetable for the capital return is shown below.

Event	Date
Effective date for the Capital Return	6 December 2023
Last day for trading of Shares entitled to participate in the Capital Return	7 December 2023
Trading in Shares on an 'ex return of capital' and 'ex dividend' basis	8 December 2023
Record date for the Capital Return	11 December 2023
Date of payment of the Capital Return	18 December 2023

**Notes:**

1. The timetable and the dates above are indicative only. The Company may vary those dates in accordance with the applicable laws in its absolute discretion and without prior notice. Changes to the above dates will be announced to the ASX and notified on the Company's website.

To ensure investors receive their entitlement to the Capital Return or any future dividend or distribution promptly, please check and update banking instructions at:

<https://investor.automic.com.au/#/home>.

Investors are strongly advised to provide Automic with banking details and to avoid the capital return payment being withheld.

- ENDS -

***This release dated 5 December 2023 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.***

---

**For more information, please contact:**

**Company/Investors**

Dr Thomas Duthy

Executive Director

[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)

+61 402 493 727

**Media**

Margie Livingston

Ignite Communications

[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)

+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter  
**@InvexThera\_ASX**

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).